Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.

Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Humans Leukemia, Lymphocytic, Chronic, B-Cell Neutropenia / chemically induced Retrospective Studies Rituximab / adverse effects
Late onset neutropenia class-effect obinutuzumab rituximab

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 22 7 2021
medline: 15 4 2022
entrez: 21 7 2021
Statut: ppublish

Résumé

Late onset neutropenia (LON) after rituximab is a previously described complication. We aimed to assess and characterize LON after obinutuzumab, a novel anti-CD20 antibody, in the real-world setting and compare it to LON after rituximab therapy. We retrospectively analyzed 330 consecutive patients with lymphoproliferative neoplasms (rituximab-treated

Identifiants

DOI: 10.1080/10428194.2021.1948037 PMID: 34284690
pubmed: 34284690
doi: 10.1080/10428194.2021.1948037
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents, Immunological 0
Rituximab 4F4X42SYQ6
obinutuzumab O43472U9X8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2921-2927

Auteurs

Shai Shimony (S)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
ORCID: 0000-0001-7245-9652

Einat Bar-Sever (E)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Tamar Berger (T)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Gilad Itchaki (G)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
ORCID: 0000-0002-9064-8139

Ronit Gurion (R)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Moshe Yeshurun (M)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Meir Lahav (M)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Pia Raanani (P)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.

Ofir Wolach (O)

Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
ORCID: 0000-0002-8662-0707

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Late onset neutropenia after rituximab and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Late onset neutropenia after rituximab and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Late onset neutropenia after rituximab and...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie chronique lymphocytaire à cellules B › Late onset neutropenia after rituximab and...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Troubles leucocytaires › Leucopénie › Agranulocytose › Neutropénie › Late onset neutropenia after rituximab and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Late onset neutropenia after rituximab and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › Late onset neutropenia after rituximab and...